Origin and Proliferation of Multiple-Drug Resistance in Bacterial Pathogens

被引:157
|
作者
Chang, Hsiao-Han [1 ]
Cohen, Ted [1 ,2 ]
Grad, Yonatan H. [1 ,3 ]
Hanage, William P. [1 ]
O'Brien, Thomas F. [4 ,5 ]
Lipsitch, Marc [1 ,6 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Ctr Communicable Dis Dynam, Boston, MA 02115 USA
[2] Yale Univ, Sch Publ Hlth, Epidemiol Microbial Dis, New Haven, CT USA
[3] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Dept Med, World Hlth Org Collaborating Ctr Surveillance Ant, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Boston, MA USA
[6] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
STREPTOCOCCUS-PNEUMONIAE; ESCHERICHIA-COLI; ANTIBIOTIC-RESISTANCE; FLUOROQUINOLONE RESISTANCE; ANTIMICROBIAL RESISTANCE; TUBERCULOSIS TREATMENT; NEISSERIA-GONORRHOEAE; EFFLUX PUMP; PHYLOGENETIC ANALYSIS; MULTIDRUG-RESISTANCE;
D O I
10.1128/MMBR.00039-14
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Many studies report the high prevalence of multiply drug-resistant (MDR) strains. Because MDR infections are often significantly harder and more expensive to treat, they represent a growing public health threat. However, for different pathogens, different underlying mechanisms are traditionally used to explain these observations, and it is unclear whether each bacterial taxon has its own mechanism(s) for multidrug resistance or whether there are common mechanisms between distantly related pathogens. In this review, we provide a systematic overview of the causes of the excess of MDR infections and define testable predictions made by each hypothetical mechanism, including experimental, epidemiological, population genomic, and other tests of these hypotheses. Better understanding the cause(s) of the excess of MDR is the first step to rational design of more effective interventions to prevent the origin and/or proliferation of MDR.
引用
收藏
页码:101 / 116
页数:16
相关论文
共 50 条
  • [31] RELEVANCE OF THE CHEMICAL CHARGE OF RHODAMINE DYES TO MULTIPLE-DRUG RESISTANCE
    LAMPIDIS, TJ
    CASTELLO, C
    DELGIGLIO, A
    PRESSMAN, BC
    VIALLET, P
    TREVORROW, KW
    VALET, GK
    TAPIERO, H
    SAVARAJ, N
    BIOCHEMICAL PHARMACOLOGY, 1989, 38 (23) : 4267 - 4271
  • [32] EMERGENCE OF MULTIPLE-DRUG RESISTANCE AMONG SALMONELLA SPECIES IN JORDAN
    SHEBABI, AA
    ZUBI, J
    ZABALAWI, G
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1985, 4 (03) : 352 - 354
  • [33] MULTIPLE-DRUG RESISTANCE IN FALCIPARUM-MALARIA FROM BRAZIL
    FERRARONI, JJ
    ALENCAR, FH
    SHRIMPTON, R
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1983, 77 (01) : 138 - 139
  • [34] USE OF NONCYTOTOXIC TRANSPORT PROBES IN A MODEL OF MULTIPLE-DRUG RESISTANCE
    SPEEG, KV
    MCGUIRE, WL
    CLINICAL RESEARCH, 1988, 36 (03): : A500 - A500
  • [35] INDUCTION OF MULTIPLE-DRUG RESISTANCE DURING ANTINEOPLASTIC CHEMOTHERAPY INVITRO
    LICHT, T
    FIEBIG, HH
    BROSS, KJ
    HERRMANN, F
    BERGER, DP
    SHOEMAKER, R
    MERTELSMANN, R
    INTERNATIONAL JOURNAL OF CANCER, 1991, 49 (04) : 630 - 637
  • [36] CLINICAL-SIGNIFICANCE OF MULTIPLE-DRUG RESISTANCE IN HUMAN CANCERS
    BENARD, J
    BOURHIS, J
    RIOU, G
    ANTICANCER RESEARCH, 1990, 10 (5A) : 1297 - 1302
  • [37] WATCH FOR MULTIPLE-DRUG ALLERGIES
    SELDERS, NJ
    RN MAGAZINE, 1984, 47 (02): : 95 - 95
  • [38] MULTIPLE-DRUG ANTIEMETIC THERAPY
    EKERT, H
    CARDEN, PA
    MITCHELL, SL
    JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (06) : 1016 - 1016
  • [39] SINGLE OR MULTIPLE-DRUG THERAPY
    MORRIS, PJ
    TRANSPLANTATION PROCEEDINGS, 1989, 21 (01) : 820 - 822
  • [40] REVERSAL OF MULTIPLE-DRUG RESISTANCE BY TOLYPORPHIN, A NOVEL CYANOBACTERIAL NATURAL PRODUCT
    SMITH, CD
    PRINSEP, MR
    CAPLAN, FR
    MOORE, RE
    PATTERSON, GML
    ONCOLOGY RESEARCH, 1994, 6 (4-5) : 211 - 218